<SEC-DOCUMENT>0001104659-24-099791.txt : 20240913
<SEC-HEADER>0001104659-24-099791.hdr.sgml : 20240913
<ACCEPTANCE-DATETIME>20240913161517
ACCESSION NUMBER:		0001104659-24-099791
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240913
FILED AS OF DATE:		20240913
DATE AS OF CHANGE:		20240913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		241297908

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2424019d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of September 2024</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Form 20-F</FONT> <FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp; &nbsp; <FONT STYLE="font-size: 10pt">Form 40-F</FONT> <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 13, 2024, CureVac N.V. (the &ldquo;Company&rdquo;) issued
a press release announcing the presentation of data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study
in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of the Company&rsquo;s Chief Scientific Officer and the Department Chair of Neurology &amp; Interdisciplinary
Neuro-Oncology at University Hospital T&uuml;bingen and Hertie Institute for Clinical Brain Research contained in Exhibit&nbsp;99.1 hereto)
is hereby incorporated by reference into the Company&rsquo;s Registration Statement on Form F-3 (File No. 333-259613).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top; width: 26%"><FONT STYLE="font-size: 10pt">/s/&nbsp;Alexander Zehnder</FONT></TD>
    <TD STYLE="vertical-align: top; width: 21%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 88%"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><A HREF="tm2424019d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><A HREF="tm2424019d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated September 13, 2024</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2424019d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2424019d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac&rsquo;s CVGBM Cancer Vaccine Induces
Promising Immune Responses in Phase 1 Study<BR>
in Glioblastoma Presented at the ESMO 2024 Congress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preliminary immunogenicity results demonstrate induction of cancer antigen-specific
T-cell responses in&nbsp;77% of evaluable patients following CVGBM monotherapy</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">84%&nbsp;of immune responses were <I>de novo</I>, observed in patients without
pre-existing T-cell activity against encoded cancer antigens</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">CVGBM was generally well tolerated up to the highest tested dose level of
100 &micro;g with no dose-limiting toxicities</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most common adverse events were mild to moderate systemic&nbsp;reactions&nbsp;such
as headache, fever and&nbsp;chills, which resolved&nbsp;within&nbsp;1&ndash;2 days post injection</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">100 &micro;g was selected as the recommended dose for the dose&nbsp;expansion
phase,&nbsp;which recently started enrollment </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>T&Uuml;BINGEN, Germany/BOSTON, USA</B> &ndash;
<B>September 13, 2024 </B>&ndash; CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;), a global biopharmaceutical company developing
a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today presented compelling data from
the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for
Medical Oncology (ESMO) Congress. The presented data include safety, tolerability and initial immunogenicity data provided for all evaluable
patients treated within Part A of the trial with CVGBM dose levels of 12-100 &micro;g. The presentation can be reviewed <U>here</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this highly aggressive and challenging cancer
indication, preliminary immunogenicity results demonstrate that treatment with CVGBM-only following chemo-radiation therapy successfully
induces cancer antigen-specific T-cell responses in&nbsp;77% of evaluable patients. Most notably, within the group of responding patients,
84% of immune responses were generated <I>de novo</I> by the CVGBM vaccination, inducing T-cell activity in patients who had no pre-existing
T-cell activity against the encoded antigens. While CD8<SUP>+</SUP> T-cells primarily attack and destroy cancer cells, CD4<SUP>+</SUP>
T-cells play a critical role in coordinating the immune response and supporting the activity of CD8<SUP>+</SUP> T-cells over time. The
majority of responding patients (69%) showed cancer antigen-specific CD8<SUP>+</SUP> responses, 31% of responding patients had CD4<SUP>+</SUP>
responses and 23% had both a CD8<SUP>+</SUP> and a CD4<SUP>+</SUP> response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;These early data are encouraging. Most
importantly, the strong <I>de novo</I> T-cell responses seen in a significant number of patients reflect the vaccine&rsquo;s ability to
break through immune tolerance to the tumor and generate a new immune response,&rdquo; said Prof. Dr. Dr. Ghazaleh Tabatabai, Chair, Department
of Neurology &amp; Interdisciplinary Neuro-Oncology, University Hospital T&uuml;bingen and Hertie Institute for Clinical Brain Research.
 &ldquo;The CVGBM safety profile is acceptable, and we are eager to see these results further validated in the next phase of the study.
This could mark an important moment in the fight against this devastating disease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2424019d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac&rsquo;s Chief Scientific Officer, Dr.
Myriam Mendila, added: &ldquo;These first-in-human data highlight for the first time the broader potential of our second-generation mRNA
backbone in cancer immunotherapy. The ability of CVGBM to elicit both CD8<SUP>+</SUP> and CD4<SUP>+</SUP> <I>de novo</I> T-cell responses
suggests that the vaccine is enhancing the immune system&rsquo;s capacity for a coordinated defense against the cancer. As we conduct
the next phase of the trial, we are building a strong foundation for future shared antigen as well as personalized cancer vaccines across
different tumor types that could offer significant benefits to patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immune activation was accompanied by a favorable
safety and tolerability profile, with no dose-limiting toxicities observed up to and including the highest tested dose of 100 &micro;g,
as confirmed by an independent Data and Safety Monitoring Board. The majority of treatment-related adverse events (TRAEs) were reported
as grade 1 (mild) and grade 2 (moderate) systemic reactions characteristic to mRNA-based therapeutics. These included headache, chills,
fever and fatigue, which resolved within 1-2 days following the injection. Seven patients reported a total of nine grade 3 (severe) TRAEs,
of which four were classified as serious adverse events (SAEs). No grade 4 or 5 adverse events occurred. Correspondingly, a 100 &micro;g
dose was selected as the recommended dose for the already initiated dose-confirmation Part B of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The open-label study is evaluating the safety
and tolerability of CVGBM in HLA-*02:01-positive patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma
or astrocytoma with a molecular signature of glioblastoma. CVGBM replaces the temozolomide maintenance phase. It is administered as a
monotherapy after surgical resection and completion of radiotherapy with or without chemotherapy. The study consists of two parts, a dose-escalation
part (Part A) and a dose-expansion part (Part B). In the fully enrolled Part A, patients received seven intramuscular vaccinations at
escalating doses in the range of 12 to 100 &micro;g on days 1, 8, 15, 29, 43, 57 and 71 and optional maintenance vaccinations in case
of non-progression or potential benefit. 16 patients were enrolled, of which 13 were evaluable for immune responses. All patients completed
surgery, 44% with complete tumor resection and 56% with only partial resection followed by chemo-radiation with temozolomide. Antigen-specific
CD4<SUP>+</SUP> and CD8<SUP>+</SUP> T-cell&nbsp;responses were assessed at relevant pre-determined timepoints until day 99. Part B of
the study is currently ongoing at the recommended dose of 100&nbsp;&micro;g.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More information can be found at clinicaltrials.gov
(<U>NCT05938387</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CVGBM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on CureVac&rsquo;s proprietary second-generation
mRNA backbone, designed for improved mRNA translation, increased protein expression and optimized induction of T-cell responses, CVGBM
encodes a single fusion protein comprising eight epitopes derived from four tumor-associated antigens (TAA) with relevance in glioblastoma,
including five HLA class I (HLA-*02:01) epitopes and three class II epitopes. CVGBM applies unmodified mRNA and is formulated within lipid
nanoparticles (LNPs). The Phase 1 proof-of-principle study of CVGBM is currently being conducted in Germany, Belgium and the Netherlands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="tm2424019d1_ex99-1img001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac (Nasdaq: CVAC) is a pioneering multinational
biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than
two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced
and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying
the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined
with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates.
It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins.
Headquartered in T&uuml;bingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information
can be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CureVac Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; text-align: justify; background-color: white">Dr. Sarah
Fakih, Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">T: +49 7071
9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">M: +49 160
90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><IMG SRC="tm2424019d1_ex99-1img001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
 &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or
its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future events or future
results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company&rsquo;s
vaccine and treatment candidates and the company&rsquo;s strategies, financing plans, cash runway expectations, growth opportunities and
market growth. In some cases, you can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or &ldquo;expect,&rdquo;
 &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo;
the negative of these terms or similar expressions. Forward-looking statements are based on management&rsquo;s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s
performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties
and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide
financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing,
expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products,
ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures
from increasing competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s
business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings,
different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned
not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s control and could cause its actual
results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made
only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or
to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information, please reference the
company&rsquo;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at <U>www.sec.gov</U>.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2424019d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2424019d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !! *<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_)@-Y.W)
MXSW[#H.,8%0NS=ECR!W/X]SGO[?C23'#.>1\RY*'9E=@):1L@D)AC\O8!<$Y
MQ\8_&S]N7]G/X'7-_IGB7QC#K7B6P222;PMX4)\0ZZA1(V6*[@L)/[/TEY1(
M#&OB/5-',B.DUN)X721_*SC/<IR' 5<PSW,*648.ES7Q%6HE'DC>TKWMJM>6
MS:_ ]')>'\_XFS"EE?"^08C/<=6FH?5\-2J5:DIN7*_=A3G9<VG-*4(K=R2U
M7V*LC"9@8B#\N6$493H,8E.2<<9/13D=JLS$L/D1&.!G>0!QCOD*".?0?ADC
M\6M5_;;_ &P/CG<+;?LL?LU:YH^CW8,MOXU\8V$%VE[;*-ABAOM:NM#\':#.
M'5E=;ZYULLL:O;^<KB1_JK]D3PM^V+8:KXRU[]J;QEHNMQ:O;Z/%X;\.V.JZ
M)+_8,D#ZE+J\$EGH7A?2]/C5K9M.C\VTU/4(;@PRR>9&^YD_/LF\3,FS_-\+
M@.&\KXOS[ XNJY5>)<KX5J9=PYA5*[YL9G&(=#ZXTG>5>A3J1JW=12DG<_1,
M_P#"#.^$<BQ6:<6<2\"<.YK2]VGP93XPPV;\:U:DJD8.C#),(ZT<OK0O+VF%
MKUXSPS@Z,Z<9V2_0&V#"% P0-\V1&05'SMT()'UYZYSS4]4M.=Y+*"1S&6<.
MV8\!-K2.4P 6&0FT-R?FSGFKM?J[M=VDIJ[M-24E)=)*2TDGNI+1[GY/2DY4
MZ<G&M%RA%N.)CR8B+:UC7CKRUD]*D;Z3NN@4444BPHHHH 82,D'L00?P'^?_
M -0J ^7O)'WL'CT&,YX]!VZ#WQRD[[0YS]QT'3^\ ?RSV_KU^;?VI/VA/!/[
M,7PIU[XK^-IF\JT2VTSP[I%N=^H>*?%&H"?^R- TZ(LY1Y7MY;S4+CR2EGI=
MG<:K,3!I,BUKAL-B,7C\/A<-%N>(Y::BE?FG.2459='=-O9)2DVDF>9F>98+
M*<OS+,<RFHX;*L)5S&<GTITJ<JU_7W'%;MNR2NT<_P"//VR/V<?AQ\3M1^$O
MC/X@1:/\0-,BL)KG1I_!_CF^BC74]+LM7LS%K&F>'+[1;DRZ?J%I*1#>OY+R
M&"?RYXI8T]R\)_$#PGXXT[^U/"VM6VHV1"ER;>YM0=X)_P!1?VUC=(3R0LEN
MA(&]=RE6/XK_ /!.S]DA?C''XM_;)_:D\-:#\0/%_P :-7U'5_".D^-]'M[_
M $:W\-:C*RW'B/\ X0^_BGTV-M9N%FL?"SR0NUOX,M]&1(]\@=?T<U7]@W]C
MW6C#<']GOX=:-<(6-O=>#]('@:ZL]I(5+:^\#WN@W<$D.T*YANUQ*'= N0J_
M29SE_#6"K4\OECN(H9A"G"EC)TE0GAH8ZFU#%T:-/W:BHTZBG[*;J+W>6RT=
M_P NX.XF\2^*,HGQ'7R[A2MD^9XNIF/"M.O0XER#%2R#%U)U\GJXG'TJV?8?
M$XBI@949U,31P&'HUY2E4I8>C"<:</L*UEW)E"2@R0%\P*02Q.TN#&1G/1\G
MO@YQ(Y\Y'VKM8 D;X$.>>RG))^C'\>M?#MQ^Q'X8TA([GX:?&W]I+X4-9><;
M+3_#GQO\9>)/#EO.0S1-<>'/B-J'C.VO[<S'SI[1KVW5P[QHT411(^ B\%_\
M%%_A7+_:FC?&[X)?M(Z%%+*9]&^)7@1?@]XD:R$CR0VVFZUX%N[[1VU!+<K:
M_;-;>6WNI$^UW$=MYQ@B\W^S<+5]W"9FY2BU"#Q,:E&K.459*I.U>E*I.WO-
MRB^:[VLG]34XGS[ )O/.$LX<$IRJU^$L;@^*HJ*O>I#"4GD?%-K>\J>'R3&U
M[-+EG.R?Z36HQ @=0'!?(*&'^-L?)T7(P??.[O4C*.<HQ]<'^N.1^)K\]E_;
MJM_ 82#]I#X(_%;X(1QL?MOC>'2(/BC\(K"%Y (GNOB?\,!KEEH]M+F-I6\2
MV&A_99VEM;B3-NTC?9?@/XB^!_B?H<'B/X?>+?#OC'0KL[[?6/"NM:?K6G.D
MI:1-MSIES=6Q<<I(OF>:LB2),B3QS1Q<]?+<;A&Y8B+]G)OEGHXM=W.#LWKK
M=1>NL5>QZ^3<59'GCC1R_&XFCB5&/M,+F&%QN!S"A.VM'&X',J.%S##8FF[Q
MK4,9AZ6*I58RA7IPJ*45Z''@(N!M'/'IR?8?7I3ZB@W",;\;MSYP"!C>V#SW
M(P3R<G)!(YJ6N%V3=MKNWH?26:T<N9K1R_F:WE\]PHHHI ?B/_P4/_:M^*<?
MQ:T[]E3X"/=:=XGU:3PM9>*=6T$QKXPU75?%UM')IWA/0KPO;#0=.M]-U'0-
M;\5:Z;N*2/1;UH&OM#@42ZO[S^SG_P $W/@M\)M.T+7?'NF6OQ4^*$,\&HZA
MK>N3_:/#^BZPJJSIX=\/2Q6NF:A'$YV+JVKZ>+N]>)K^&UTSSULH/EW_ (*.
M_ #XC^!?C;8?MG_"B!=8&B7O@G4_%]C]FEU&X\/^(?!%C'::3K5YIV DWA74
M=!@L]+U22)]]K<@R2>6)HW/W!^RU^W;\(?VB=*TW2Y]2M/!GQ4"P_P!M>!]7
MNE47NJ2IYEU)X6OYG+:IIXDR\<<9:>S#BQE1V@D*_P KY5+):OBOQK2\58K_
M %@AF6$7A[#BA1_U2>2O%3>32R92:IO.'!T)5+^^ZNL;SYT?V3Q'#B7!> 'A
M[B?!5T_]3JN%Q4O&^IPVZRXH7'#IR>!AQF\(O[:CD2P#K?V&\0_[!]G912I^
M\_M=/+$?DJB* 6@2&(Q/YEOYD=MF&$@,L,)41^6&,0VN$ 3I\E_LI?%_QK\6
M;/X[2^,[[3-0E\"_M%_$CX;^');?3I+%K;P[X9MO#US80-+&'&5ENIF-Q(H,
MG'SGRSM^MS)#&K*CPR7<$DK8A5(3M2<23*H V8*$AP!GS/,9L@MM_)/X8?%3
MQ!^R7XE^/'@?QU^S]\>_$MOX\^.OCCXF^'/$/PU\!/XX\+7?AGQ196M[IUO/
MJ(UFUEMYK&'39+2X*VT92]22 [UC663]NXLSB&1\0<,XC'YC3P^07XN?$BE?
MV<8O(,%/+%."O.,8N,E3?+RS<E=Q3;C_ #CP-DDN*.&.,\-E&#GFO$5^$:O#
M^'G4X:ABN5<09E#BZ+GB,]X>@ZT<IJ8)5%#$U)*45*7-&+E4^NOVQ/BOXZ^#
MGPHTSQ=X&NM/L]:N/B)X$\-75QJ6ERZIFQU[Q!;Z?JAA\Z-5C86BS*LS*IB8
M;@.C-YE^UC\6?B_X9^+W[,/PN^$_C#2/!H^-&J^*],UK7=1\*6'BM;:33X/#
MYMY5M)KO3[A5(U3S(6BNB\A4(JA40+X!\;OC3XA_:PT'P[\'/AY^SS^T'H6L
MWOQ%\$>(]3\1?$?X?R>%?"F@:+X=UZ&\?4[S63?WT&G2&WA3[,/.65XRF0GG
M.J]A^V]\%;WXS_'G]D;P_>>&?%][X,GOOB#IGC+6O#L5\IT73[ZV\,")9==L
M96BTB%UM7V3OY;W8;S2HD#&OS'BG/,]SK_73-^$9\09ME[7AGE^ P>'P_$N0
M4>>/$,H<82PF94HTHUZ<\BJT)RQ>"INFZ?)-57"<9GZWP1PQP_PWF/ V4<>X
M?A7(,=#!^*V9YM/,LIX5S^=*"X7C4X-EGV0_ZVXNEFLJ6?T:RR*G6Q<OK-9^
MY+$<R;]-\9^"OVQ_!_A3Q5XRD_:G\"7Q\-Z!J7B5+34OV>]&L=-U0:#IQU1[
M>]NCXMN;^QEECL7LH)DO)Y'WI+&D(:.*+D;K]KGX@6?_  3_ +']J1]#T"W\
M>7ENZS6BQW/_  CRW4OQ)F\"6^ORV U"$SV\D=LMZEO<:TD,9<1R.L),)Q_B
MM_P3E^!]C\._B#J?A;_A8]YXCTWPIXEU;PW8?\);?^)K6?6K;1[F^TF*71]4
MTR\M-76:]L=-:30C(?M[(F8?.NA))@ZUX"^+?Q<_X)EV?@X>"]GQ-&B:(5\(
M3:)#X7O]43X??$ZSU.ST6V\-1QVT&E2ZQX:T..YM;%+>(W,UTS(I-R5.\*'%
MF39MQ-A\+@>)LIABN ,ZQ&'_ .,LX@XUP_\ ;3S23RB?M,?&>:9+B*>4M3>%
MRNG4A2J2G3HM_5H2GTY;'PTS;"<%YCC\=PEQ#A_^(R\ Y5Q+]?X%X;\+JL.'
M987'0E0Q.7Y-Q3_PI9)B,QI+^UL^SIX?+LKS2-#*JU1PKR=/T+3;SXTW-M#<
M77_!0'X(:==.D?VBR?X2?#,6NGW93]_96A/Q2NKIC:S"2WDF>-)))8WED6-G
M*+WWB[3?VH)/V>O&M_\ ##]HCP/\3/BI8W4GB3PGXKT+X<Z!%X?U?3=+MI(M
M4\!:O8VNN>-[6_EUN1;F+3;_ $VSTN:SU&WBM[L2XEE;Y(LO'7[)T=M!'?\
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M.S_9>_9U@O-2\6^)M&=+A/$>M/>66DS:A;7R%S:7WBB:VU'PQX(UN-I9-/\
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MC]2)P#(S;4;8HV)*R(OGE6CCV$@G_2DGEMFD*M@Q[54D$'Y$_9-^#WC'X/\
MA+XS?#GQU;:5=^&K[]I;]I/QY\,KB*X&KQ:O\+_CK\3M6^.5G8:B"52P71/%
M'Q1\5>!#X<U!C]OLO#<&HQ-):7H! /@:Z_X*S>.?#%IX:N/BK^S1#\&_^%R?
M'G0/A-\!?%?Q'^*UCX*^'6L>#(?AW:^//BK\8_&GB?XN^&/A)HEOIWPJL+^;
M3M.\)?#O7_'*_'OQ?9WF@?L_?$/XC_#FP/Q;7Z.\:?MUR^!=#\'6&L> K/6/
M'D_ACX17WC/P4/%FI^&?B!K5[\3)K^2/PW\ ?AQK.A:UK_Q<^)&CZ'H5S\0M
M=^#7B+5_ 'C%/!&L>%[+5[C4O$-Y?:7;?>W@?X?^!? /A^S\-^ _!/A;P-X9
MLIC/9^&/"OAS1_#^CV%Z)59I[72]$6/3;26.8R&X^S1AI+IKB>5VGDE9_$I%
M\8Z!^V-'/:^$+J[^&_Q*_9TNO^$A\?0@'3_"_C[X(_$G36\+^%-1D)5;"_\
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@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
